Open AccessAn Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
Author(s) -
Emerson Y. Chen,
Vikram Raghunathan,
Vinay Prasad
Publication year - 2019
Publication title -
jama internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.14
H-Index - 342
eISSN - 2168-6114
pISSN - 2168-6106
DOI - 10.1001/jamainternmed.2019.0583
Subject(s) - medicine , surrogate endpoint , interquartile range , food and drug administration , clinical endpoint , cancer , retrospective cohort study , clinical trial , oncology , surgery , pharmacology
Approximately one-third of cancer drugs are approved based on response rate (RR)-the percentage of patients whose tumors shrink beyond an arbitrary threshold-typically assessed in a single-arm study.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom